Profit from the long-term potential in cannabis

Nawan Butt, portfolio manager of the Medical Cannabis and Wellness UCITS ETF, picks some of his favourite cannabis stocks.

As the global economy wrestles with the fallout from Covid-19, investors desperate for good news should consider the secular growth story of cannabis. Over the past few years stock prices in the sector have been volatile, not least because the attitude of regulators was hard to gauge. But now, with medical cannabis deemed an essential service in at least 21 US states, the support from the authorities has become clear. Policymakers’ support should limit the scope for share-price falls and bolster the investment case for pot stocks and exchange-traded funds (ETFs).

Try a dab of CBD 

Using marijuana for medicinal purposes doesn’t only involve smoking it. Cannabidiol (CBD) is a non-intoxicating oil derived from cannabis and hemp and is considered helpful for conditions ranging from anxiety to acne. This brings us to Abacus Health Products. Abacus holds a unique position in the complex regulatory structure of US CBD legalisation: it boasts the only CBD topical products in the US market that have been approved by the federal Food and Drug Administration (FDA).

Recently, the biggest hemp and CBD company in the US, Charlotte’s Web (TSX: CWEB) agreed to acquire Abacus. Charlotte’s Web has the most recognised brand in the US for CBD, with an emphasis on its effectiveness against childhood epilepsy. The combined company will account for 35% of the CBD market, selling its products in 15,000 locations and online.

Tetra Bio-Pharma (CVE: TBP) focuses on cannabinoid-derived treatments to help address chronic pain and eye problems, two of the largest market segments in medical cannabis. Its premier drug (CAUMZ) targets pain caused by advanced and incurable cancer and is in the process of gaining FDA approval; it has been accepted into the “Fast Track” programme. This designation expedites the review process and gives patients rapid access to new drugs. 

Tetra is also developing botanical drugs for conditions currently ineffectively serviced by opioids and steroids. With the success of CAUMZ, Tetra Bio-Pharma will be able to reduce the stigma of cannabis-based medicine. 

Growth in the cannabis greenhouse

The medical cannabis and CBD wellness boom in the US has had a positive effect across the supply chain. GrowGeneration (Nasdaq: GRWG) allows cannabis groups to build and maintain regulated cultivation sites throughout the US. 

It is a hydroponic equipment supplier with 27 garden centres across ten American states. Hydroponics has been a flourishing sub-segment of the market pioneered by the likes of Scotts Miracle Grows. GrowGeneration supplies thousands of products, including organic nutrients, soils, advanced lighting technology and state-of-the-art equipment used by commercial and home growers. It also offers greenhouse design and harvesting services for growers at any scale.

In its latest quarter, GrowGeneration managed to produce same-store sales growth of 62% year-on-year, along with positive net income. An industry with this kind of growth trajectory is a highly attractive long-term bet and a key component of our ETF’s portfolio. 

Recommended

Iris Apfel: an inspiration to young fashionistas
People

Iris Apfel: an inspiration to young fashionistas

Iris Apfel made her name as a high-society interior designer before a show at the New York Met turned her into a fashion influencer. At 100 years old,…
19 Sep 2021
Warsaw and Stockholm: the unexpected new threats to the City of London
UK stockmarkets

Warsaw and Stockholm: the unexpected new threats to the City of London

London has seen off challenges from Frankfurt and Paris, but two other booming financial centres are a bigger threat, says Matthew Lynn.
19 Sep 2021
The charts that matter: more pain for goldbugs
Economy

The charts that matter: more pain for goldbugs

Gold investors saw more disappointment this week as the yellow metal took a tumble. Here’s what’s happened to the charts that matter most to the globa…
18 Sep 2021
The new social-care levy: an unfair tax that protects the “assetocracy”
National Insurance

The new social-care levy: an unfair tax that protects the “assetocracy”

The government’s regressive social-care levy will make Britain’s tax system even more complex. Root-and-branch reform is long overdue.
18 Sep 2021

Most Popular

The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
How to stop recurring subscriptions becoming a drain on your money
Personal finance

How to stop recurring subscriptions becoming a drain on your money

Tracking and pruning subscriptions isn’t as easy as it sounds. Here's how to take charge.
14 Sep 2021